Holen Sie sich die Stockscreener-App
139.37
2.64%
3.59
Handel nachbörslich:
139.58
0.21
+0.15%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt ILMN?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$135.78
Offen:
$135.45
24-Stunden-Volumen:
2.01M
Relative Volume:
1.08
Marktkapitalisierung:
$21.17B
Einnahmen:
$4.34B
Nettoeinkommen (Verlust:
$850.00M
KGV:
25.51
EPS:
5.4635
Netto-Cashflow:
$921.00M
1W Leistung:
+8.44%
1M Leistung:
+9.41%
6M Leistung:
+19.26%
1J Leistung:
+78.95%
1-Tages-Spanne:
$133.97
$140.84
1-Wochen-Bereich:
$119.14
$140.84
52-Wochen-Spanne:
$73.86
$155.53
Illumina Inc Stock (ILMN) Company Profile
Firmenname
Illumina Inc
Sektor
Branche
Telefon
(858) 202-4500
Adresse
5200 ILLUMINA WAY, SAN DIEGO, CA
Compare ILMN vs TMO, DHR, IDXX, A, NTRA
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ILMN
Illumina Inc
|
139.37 | 20.63B | 4.34B | 850.00M | 921.00M | 5.4635 |
TMO
Thermo Fisher Scientific Inc
|
462.60 | 174.37B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
174.04 | 123.97B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
563.12 | 45.07B | 4.30B | 1.06B | 1.04B | 13.08 |
A
Agilent Technologies Inc
|
112.18 | 32.36B | 7.07B | 1.29B | 993.00M | 4.5355 |
NTRA
Natera Inc
|
211.56 | 29.60B | 2.31B | -208.16M | 76.11M | -1.5366 |
Illumina Inc Stock (ILMN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-08-12 | Herabstufung | Daiwa Securities | Outperform → Neutral |
| 2025-07-11 | Herabstufung | Scotiabank | Sector Outperform → Sector Perform |
| 2025-03-04 | Bestätigt | Citigroup | Neutral |
| 2025-02-28 | Herabstufung | HSBC Securities | Buy → Hold |
| 2025-02-10 | Herabstufung | Barclays | Equal Weight → Underweight |
| 2025-02-07 | Herabstufung | TD Cowen | Buy → Hold |
| 2024-12-11 | Herabstufung | Citigroup | Buy → Neutral |
| 2024-11-12 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2024-10-17 | Hochstufung | HSBC Securities | Hold → Buy |
| 2024-08-28 | Hochstufung | Argus | Hold → Buy |
| 2024-08-16 | Hochstufung | Daiwa Securities | Neutral → Buy |
| 2024-08-14 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2024-08-14 | Hochstufung | TD Cowen | Hold → Buy |
| 2024-07-10 | Hochstufung | Citigroup | Neutral → Buy |
| 2024-06-03 | Fortgesetzt | Jefferies | Hold |
| 2024-01-16 | Herabstufung | HSBC Securities | Buy → Hold |
| 2024-01-04 | Herabstufung | TD Cowen | Outperform → Market Perform |
| 2023-12-18 | Hochstufung | Scotiabank | Sector Perform → Sector Outperform |
| 2023-12-15 | Hochstufung | Bernstein | Underperform → Mkt Perform |
| 2023-12-14 | Eingeleitet | Guggenheim | Buy |
| 2023-12-14 | Eingeleitet | Stephens | Overweight |
| 2023-12-13 | Eingeleitet | Wolfe Research | Outperform |
| 2023-12-12 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2023-12-11 | Hochstufung | Citigroup | Sell → Neutral |
| 2023-11-10 | Herabstufung | Canaccord Genuity | Buy → Hold |
| 2023-09-28 | Eingeleitet | Bernstein | Underperform |
| 2023-07-05 | Fortgesetzt | JP Morgan | Neutral |
| 2023-01-25 | Herabstufung | Argus | Buy → Hold |
| 2023-01-05 | Eingeleitet | Scotiabank | Sector Perform |
| 2022-12-12 | Herabstufung | Citigroup | Neutral → Sell |
| 2022-12-07 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2022-10-04 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2022-09-28 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2022-08-25 | Eingeleitet | Credit Suisse | Neutral |
| 2022-07-13 | Herabstufung | Barclays | Equal Weight → Underweight |
| 2022-01-18 | Hochstufung | Stifel | Hold → Buy |
| 2022-01-11 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2022-01-07 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2022-01-06 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2022-01-06 | Fortgesetzt | Piper Sandler | Overweight |
| 2021-10-15 | Fortgesetzt | Cowen | Outperform |
| 2021-08-19 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2021-06-01 | Hochstufung | Evercore ISI | Underperform → In-line |
| 2021-03-31 | Herabstufung | Atlantic Equities | Overweight → Neutral |
| 2021-03-31 | Hochstufung | Canaccord Genuity | Hold → Buy |
| 2021-03-03 | Eingeleitet | Barclays | Underweight |
| 2020-12-22 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2020-12-17 | Hochstufung | BTIG Research | Neutral → Buy |
| 2020-10-13 | Herabstufung | Guggenheim | Buy → Neutral |
| 2020-09-30 | Eingeleitet | Atlantic Equities | Overweight |
| 2020-09-29 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2020-09-22 | Herabstufung | Stifel | Buy → Hold |
| 2020-09-22 | Herabstufung | UBS | Buy → Neutral |
| 2020-09-21 | Hochstufung | Guggenheim | Neutral → Buy |
| 2020-09-21 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-09-09 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2020-08-07 | Herabstufung | Evercore ISI | In-line → Underperform |
| 2020-08-07 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2020-07-07 | Herabstufung | Guggenheim | Buy → Neutral |
| 2020-04-24 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-04-21 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2020-01-08 | Eingeleitet | Wells Fargo | Underweight |
| 2020-01-07 | Eingeleitet | Citigroup | Buy |
| 2020-01-02 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2019-11-15 | Eingeleitet | Stifel | Buy |
| 2019-10-25 | Eingeleitet | Guggenheim | Buy |
Alle ansehen
Illumina Inc Aktie (ILMN) Neueste Nachrichten
Illumina, Inc. Q1 2026 Financial Report: Earnings, Revenue, Risk Factors & Forward-Looking Statements 18 24 37 - Minichart
Illumina Partners with Florida State University Lab for Rare Disease Genome Sequencing - Clinical Lab Products
Genomics Market size is anticipated to reach US$ 83.61 billion - openPR.com
Illumina (ILMN) Q1 2026 Earnings: Revenue Beat and Raised GuidanceNews and Statistics - IndexBox
Illumina, Inc. 2026 Q1ResultsEarnings Call Presentation (NASDAQ:ILMN) 2026-05-03 - Seeking Alpha
ILMN Q1 Deep Dive: Clinical Sequencing Fuels Growth as NovaSeq X Demand Surges - Yahoo Finance
Illumina revenue up 4.8% to USD 1.09B in Q1 2026 - Medical Buyer
Jennison Associates LLC Has $26.21 Million Stock Position in Illumina, Inc. $ILMN - MarketBeat
[10-Q] ILLUMINA, INC. Quarterly Earnings Report - Stock Titan
Illumina Inc. stock outperforms competitors on strong trading day - MarketWatch
Illumina jumps 7.1% as Q1 results top expectations and full-year outlook rises - Quiver Quantitative
Illumina (NASDAQ:ILMN) Stock Price Expected to Rise, JPMorgan Chase & Co. Analyst Says - MarketBeat
Here’s Why Illumina Stock Could Deliver 8% Annual Returns Through 2028 - TIKR.com
Canaccord cuts Illumina stock price target on competition concerns - Investing.com UK
Illumina, Inc. (NASDAQ:ILMN) Q1 2026 Earnings Call Transcript - Insider Monkey
Canaccord cuts Illumina stock price target on competition concerns By Investing.com - Investing.com Canada
Illumina Q1 2026 earnings preview - MSN
Evercore ISI raises Illumina stock price target on strong results By Investing.com - Investing.com Canada
Evercore ISI raises Illumina stock price target on strong results - Investing.com
Florida Hospital Association adds Gaye Walker as communications VP - Florida Politics
MSN Money - MSN
Illumina (NASDAQ:ILMN) Releases Earnings Results, Beats Estimates By $0.10 EPS - MarketBeat
Illumina (ILMN) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates - Yahoo News Malaysia
Illumina Q1 Earnings Call Highlights - Yahoo Finance
Illumina Q1 2026 slides: earnings beat on clinical strength, margins expand - Investing.com India
Illumina (ILMN) Q1 2026 Earnings Transcript - AOL.com
Illumina (ILMN) Tops Q1 Earnings and Revenue Estimates - Yahoo Finance
Illumina (NASDAQ:ILMN) Issues FY 2026 Earnings Guidance - MarketBeat
Earnings call transcript: Illumina beats Q1 2026 estimates, stock rises - Investing.com
Earnings call transcript: Illumina beats Q1 2026 estimates, stock rises By Investing.com - Investing.com South Africa
Illumina (NASDAQ:ILMN) Posts Better-Than-Expected Sales In Q1 CY2026 - TradingView
Illumina lifts 2026 outlook and expands share buybacks - TipRanks
Illumina Q1 Non-GAAP Earnings, Revenue Rise; Raises 2026 Outlook - marketscreener.com
(ILMN) Illumina Expects Fiscal 2026 Adjusted EPS Range $5.15-$5.30, vs. FactSet Est of $5.12 - marketscreener.com
Illumina: Q1 Earnings Snapshot - marketscreener.com
Earnings Flash (ILMN) Illumina, Inc. Reports Q1 Revenue $1.09B, vs. FactSet Est of $1.07B - marketscreener.com
[8-K] ILLUMINA, INC. Reports Material Event - Stock Titan
Tranche Update on Illumina, Inc.'s Equity Buyback Plan announced on November 6, 2024. - marketscreener.com
Illumina Reports Financial Results for First Quarter of Fiscal Year 2026 - PR Newswire
Tempus AI vs. Illumina: Which Oncology Stock Is Worth Buying Now? - Yahoo Finance
Illumina set to report earnings amid rising Roche competition By Investing.com - Investing.com Australia
Vanguard reports 7.94M shares in Illumina (ILMN) Schedule 13G - Stock Titan
Illumina Inc. Stock (US4523271090): Q1 2026 Earnings Release Expected Today - AD HOC NEWS
Illumina, Inc. $ILMN Shares Sold by Pictet Asset Management Holding SA - MarketBeat
Vanguard Group Inc. Lowers Stake in Illumina, Inc. $ILMN - MarketBeat
ILMN Stock Price, Quote & Chart | ILLUMINA INC (NASDAQ:ILMN) - ChartMill
Illumina Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Discipline and Rules-Based Execution in ILMN Response - Stock Traders Daily
Illumina (ILMN) Q1 Earnings Report Preview: What To Look For - Yahoo Finance
Will DRAGEN v4.5’s ML-Powered Genomics Upgrade Reshape Illumina’s (ILMN) Precision Medicine Narrative? - Yahoo Finance
Unlocking Q1 Potential of Illumina (ILMN): Exploring Wall Street Estimates for Key Metrics - Yahoo Finance
Finanzdaten der Illumina Inc-Aktie (ILMN)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.61%
2.01%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):